NASDAQ · SABS
SAB Biotherapeutics, Inc.
Healthcare · Biotechnology
$2.98▼ 2.61% ($0.08)at close
After hours$3.00▲ 0.67%7:30 PM ET
Market cap
$271.14M
P/E
13.77
EPS (TTM)
-$0.16
Next earnings
Nov 13, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need current revenue and shares outstanding to build the revenue-driven FCFF model.
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
Data notes
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $2.98 · Price Oct 2, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 48.26% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow declined 137.04% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Market multiples
Stock splits
Every 10 shares became 1
Profitability & growth
Analyst consensus
7
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 13, 2026
Q3 FY26 · EPS est -$0.27 · Revenue est $125K
View
Institutional Sentiment
SAB Biotherapeutics, Inc. · SABS
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.